Treating uncomplicated malaria in children: Comparing artemisinin-based combination therapies

Current Opinion in Pediatrics

Volumn 22, Issue 6, 2010, Pages 798-803

  Yeka, Adoke ^a   Harris, Jamal C ^b  

^a Uganda Malaria Surveillance Project   (Uganda)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

artemisinin based combination therapy; home based malaria management; malaria; malaria diagnostics

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTEMISININ DERIVATIVE; ARTESUNATE; ARTESUNATE PLUS FANSIDAR; BENFLUMETOL; CHLOROQUINE; CLINDAMYCIN; DIHYDROARTEMISININ; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; FANSIDAR; MEFLOQUINE; PIPERAQUINE; PRIMAQUINE; QUININE; TETRACYCLINE; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; AFRICA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; INFECTION RISK; MALARIA; MALARIA CONTROL; MONOTHERAPY; MULTIDRUG RESISTANCE; NEGRO; NEUTROPENIA; PARASITE TRANSMISSION; PARASITEMIA; PATIENT COMPLIANCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RISK FACTOR; RISK REDUCTION; SELF EVALUATION; TABLET; UGANDA; UNSPECIFIED SIDE EFFECT;

AFRICA SOUTH OF THE SAHARA; ANTIMALARIALS; ARTEMISININS; ASIA, SOUTHEASTERN; CHILD; DRUG COMBINATIONS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALARIA, FALCIPARUM; PATIENT ACCEPTANCE OF HEALTH CARE;

EID: 78649498394     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32833fac44     Document Type: Review

References (46)

1. World Health Organization. Guidelines for the treatment of malaria. 2nd ed. Geneva: WHO Press; 2010. Newly revised WHO guidelines for the management of malaria released in March 2010.
2. Sinclair D, Zani B, Donegan S, et al. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009: CD007483. Systematic review of ACT trials published through March 2009 summarizing 50 trials. ACTs are one of the classes of drugs most in history.
3. Eastman RT, Fidock DA. Artemisinin-based combination therapies: A vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009; 7:864-874. A comprehensive review of the pharmacologic properties of artemisinin derivatives and their partner drugs.
4. Adjei GO, Goka BQ, Binka F, Kurtzhals JA. Artemether-lumefantrine: An oral antimalarial for uncomplicated malaria in children. Expert Rev Anti Infect Ther 2009; 7:669-681. A review of the evidence for artemether-lumefantrine use in children.
5. Kefyalew T, Animut A, Tamene T, et al. Efficacy of six-dose regimen of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria, three years after its introduction into Ethiopia. Parasite 2009; 16:129-134.
6. Premji ZG. Coartem: The journey to the clinic. Malar J 2009; 8 (Suppl 1):S3.
7. Valecha N, Srivastava P,MohantySS, et al. Therapeutic efficacy of artemether- lumefantrine in uncomplicated falciparum malaria in India. Malar J 2009; 8: 107.
8. Falade C, Manyando C. Safety profile of Coartem: The evidence base. Malar J 2009; 8 (Suppl. 1):S6. Provides postmarketing data on artemether-lumefantrine safety. Part of Novartis sponsored supplement.
9. Zwang J, Olliaro P, Barennes H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: A multicentre analysis. Malar J 2009; 8:203. Multicenter study that demonstrates that, while artesunate-amodiaquine is generally efficacious, it does not meet WHO efficacy standards in all countries and regions studied in sub-Saharan Africa.
10. Sirima SB, Tiono AB, Gansane A, et al. The efficacy and safety of a new fixeddose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. Malar J 2009; 8:48.
11. Thwing JI, Odero CO, Odhiambo FO, et al. In-vivo efficacy of amodiaquine- artesunate in children with uncomplicated Plasmodium falciparum malaria in western Kenya. Trop Med Int Health 2009; 14:294-300.
12. Ndiaye JL, Randrianarivelojosia M, Sagara I, et al. Randomized, multicentre assessment of the efficacy and safety of ASAQ: A fixed-dose artesunate- amodiaquine combination therapy in the treatment of uncomplicated Plasmodium falciparum malaria. Malar J 2009; 8:125. Demonstrates the efficacy of fixed dose artesunate-amodiaquine.
13. Gasasira AF, Kamya MR, Achan J, et al. High risk of neutropenia in HIVinfected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis 2008; 46:985-991.
14. Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: A randomised, noninferiority trial. PLoS One 2009; 4:e7871. Demonstrates the efficacy and safety of dihydroartemisinin-piperaquine.
15. Zwang J, Ashley EA, Karema C, et al. Safety and efficacy of dihydroartemisinin- piperaquine in falciparum malaria: A prospective multicentre individual patient data analysis. PLoS One 2009; 4:e6358. Demonstrates the efficacy and safety of dihydroartemisinin-piperaquine.
16. Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: A longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009; 49:1629-1637. Compares the efficacy and safety of artemether-lumefantrine and dihydroartemisinin- piperaquine and evaluates the prophylactic effect of ACTs whose different partner drug half-lives differ greatly. Study highlights the need for further study of the long-term impact of ACT options.
17. Price RN, Douglas NM. Artemisinin combination therapy for malaria: Beyond good efficacy. Clin Infect Dis 2009; 49:1638-1640.
18. Thanh NX, Trung TN, Phong NC, et al. Open label randomized comparison of dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in central Vietnam. Trop Med Int Health 2009; 14:504-511.
19. Trung TN, Tan B, Van Phuc D, Song JP. A randomized, controlled trial of artemisinin-piperaquine vs dihydroartemisinin-piperaquine phosphate in treatment of falciparum malaria. Chin J Integr Med 2009; 15:189-192.
20. White NJ. How antimalarial drug resistance affects posttreatment prophylaxis. Malar J 2008; 7:9.
21. Okell LC, Drakeley CJ, Bousema T, et al. Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med 2008; 5:e226; discussion e226.
22. Okell LC, Drakeley CJ, Ghani AC, et al. Reduction of transmission from malaria patients by artemisinin combination therapies: A pooled analysis of six randomized trials. Malar J 2008; 7:125.
23. Song J, Socheat D, Tan B, et al. Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine. Malar J 2010; 9:57. Pilot study assessing the impact and feasibility of mass distribution of ACT as part of malaria elimination strategy.
24. Kamat VR, Nyato DJ. Community response to artemisinin-based combination therapy for childhood malaria: A case study from Dar es Salaam, Tanzania. Malar J 2010; 9:61.
25. Adjei GO, Darkwah AK, Goka BQ, et al. Parents' perceptions, attitudes and acceptability of treatment of childhood malaria with artemisinin combination therapies in Ghana. Ghana Med J 2009; 43:99-106.
26. Chuma J, Okungu V, Molyneux C. Barriers to prompt and effective malaria treatment among the poorest population in Kenya. Malar J 2010; 9:144.
27. Zurovac D, Ndhlovu M, Rowe AK, et al. Treatment of paediatric malaria during a period of drug transition to artemether-lumefantrine in Zambia: Cross sectional study. BMJ 2005; 331:734.
28. Zurovac D, Ndhlovu M, Sipilanyambe N, et al. Paediatric malaria casemanagement with artemether-lumefantrine in Zambia: A repeat crosssectional study. Malar J 2007; 6:31.
29. Zurovac D, Njogu J, Akhwale W, et al. Effects of revised diagnostic recommendations on malaria treatment practices across age groups in Kenya. Trop Med Int Health 2008; 13:784-787.
30. Zurovac D, Njogu J, Akhwale W, et al. Translation of artemether- lumefantrine treatment policy into paediatric clinical practice: An early experience from Kenya. Trop Med Int Health 2008; 13:99-107.
31. Zurovac D, Tibenderana JK, Nankabirwa J, et al. Malaria case-managementunder artemether-lumefantrine treatment policy in Uganda. Malar J 2008; 7:181.
32. Kokwaro G. Ongoing challenges in the management of malaria. Malar J 2009; 8 (Suppl 1):S2.
33. Ogouyemi-Hounto A, Kinde-Gazard D, Nahum A, et al. Management of malaria in Benin: Evaluation of the practices of healthcare professionals following the introduction of artemisinin derivatives. Med Trop (Mars) 2009; 69:561-564.
34. World Health Organization. World malaria report 2009. Geneva:WHOPress; 2009. http://whqlibdoc.who.int/publications/2009/9789241563901-eng. pdf. [Accessed July 2010] WHO summary of trends in malaria epidemiology and care.
35. Nankabirwa J, Zurovac D, Njogu JN, et al. Malaria misdiagnosis in Uganda: Implications for policy change. Malar J 2009; 8:66. Cross-sectional study that measured the amount of misdiagnosis that occurs using presumptive treatment of fever in Uganda.
36. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361:455-467. First published evidence of in-vivo resistance to an artemisinin derivative.
37. Pagnoni F. Malaria treatment: No place like home. Trends Parasitol 2009; 25:115-119. Editorial written by WHO discussing the role of HMM in malaria control.
38. Ajayi IO, Browne EN, Garshong B, et al. Feasibility and acceptability of artemisinin-based combination therapy for the home management of malaria in four African sites. Malar J 2008; 7:6.
39. Willcox ML, Sanogo F, Graz B, et al. Rapid diagnostic tests for the homebased management of malaria, in a high-transmission area. Ann Trop Med Parasitol 2009; 103:3-16. Evaluation of the use of RDTs in HMM in Sudan.
40. Staedke SG, Mwebaza N, Kamya MR, et al. Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: A randomised controlled trial. Lancet 2009; 373:1623-1631. Randomized control trial (RCT) of the use of artemether-lumefantrine-basedHMM without RDTs in Kampala, Uganda. Highlights the need for HMM strategies to be targeted balancing local epidemiologic trends and health system resources.
41. Elmardi KA, Malik EM, Abdelgadir T, et al. Feasibility and acceptability of home-based management of malaria strategy adapted to Sudan's conditions using artemisinin-based combination therapy and rapid diagnostic test. Malar J 2009; 8:39.
42. Achan J, Tibenderana JK, Kyabayinze D, et al. Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: Randomised trial. BMJ 2009; 339:b2763. RCT of artemether-lumefantrine vs. quinine that demonstrates the relative efficacy of quinine monotherapy as a treatment for uncomplicated P. falciparum. Suggests the need for increased focus on provision of effective second-line therapy in Africa.
43. Yeka A, Achan J, D'Alessandro U, Talisuna AO. Quinine monotherapy for treating uncomplicated malaria in the era of artemisinin-based combination therapy: An appropriate public health policy? Lancet Infect Dis 2009; 9:448-452.
44. Barennes H, Srour LM, Pussard E. Is it too soon to eliminate quinine? Lancet Infect Dis 2010; 10:141-142.
45. Abdulla S, Sagara I. Dispersible formulation of artemether/lumefantrine: Specifically developed for infants and young children. Malar J 2009; 8 (Suppl. 1): S7. Describes the development of infant-friendly formulation of artemether-lumefantrine.
46. Makanga M, Krudsood S. The clinical efficacy of artemether/lumefantrine (Coartem). Malar J 2009; 8 (Suppl 1):S5.